Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Therapy with a GLP-1 RA or sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) that has proven CV benefit is recommended for initial therapy, with or without metformin based on glycemic needs, in patients with indicators of high-risk or established CV disease
An initial 4-8 week assessment period allows evaluation of individual response and tolerance before committing to extended therapy
Evidence: Systematic review shows B12 significantly improves diabetic neuropathy symptoms vs placebo (Hasan et al., 2019)
Please ensure that you seek medical advice from your primary care provider before starting any weight loss program
Rapid or excessive weight loss is generally not healthy or sustainable
During aging, metabolic function gradually declines, leading to insulin resistance, fat accumulation, and insufficient energy metabolism
US$ 25.58
US$ 29.25
US$ 21.61
US$ 28.33
US$ 25.56
US$ 28.81
